newsfilter
← Latest News
PR Newswire·

Tetra Bio-Pharma and Cannvalate Enter Into Partnership

Cannvalate to invest CAD$7.5M in Tetra. Cannvalate to launch and manage QIXLEEF™ and CAUMZ™ clinical trials in Australia. The Company to benefit from a 43.5% tax credit on all money spent on clinical trials in Australia. OTTAWA, ON, May 5, 2022